CTOs on the Move

Perlegen Sciences

www.perlegen.com

 
Perlegen Sciences, Inc. is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

AmProx

AmProx is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rosetta Genomics

Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.   Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.   Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.

Immunai

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Nexstim

Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy